Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept

Affiliation auteurs!!!! Error affiliation !!!!
TitreRisk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept
Type de publicationJournal Article
Year of Publication2022
AuteursRempenault C, Lukas C, Combe B, Herrero A, Pane I, Schaeverbeke T, Wendling D, Pham T, Gottenberg J-E, Mariette X, Morel J, Investig FSoc Rheuma
JournalRHEUMATOLOGY
Volume61
Pagination953-962
Date PublishedMAR 2
Type of ArticleArticle
ISSN1462-0324
Mots-clésdiverticulitis, gastrointestinal perforation, Rheumatoid arthritis, tocilizumab
Résumé

{Objective To compare the risk of diverticulitis and gastrointestinal perforation (GIP) in RA treated with tocilizumab (TCZ) compared with rituximab (RTX) and abatacept (ABA). Methods We conducted a population-based study using three observational French registries on TCZ, RTX and ABA in RA. Using a propensity score approach, we compared the risk of diverticulitis or GIP in these patients. Results With inverse probability weighting, there was an increased risk of diverticulitis in TCZ-treated patients compared with RTX- or ABA-treated patients [hazard ratio (HR)=3.1 (95% CI: 1.5, 6.3)
DOI10.1093/rheumatology/keab438